• Issue

    British Journal of Dermatology: Volume 187, Issue 6

    i-vi, 835-1084, e193-e221
    December 2022
Previous Issue
Export Citation(s)Download PDF(s)

Issue Information

Free Access

Issue Information

  • Pages: i-iv
  • First Published: 04 December 2022

Editor's Choice

Editor's Choice

  • Page: vi
  • First Published: 04 December 2022

EDITORIAL

Free Access

Patient engagement with the BJD: encouraging the patient voice and readership

Olivia Hughes,  Laura Prescott,  Bernd W.M. Arents, 
  • Pages: 835-836
  • First Published: 04 December 2022
Patient engagement with the BJD: encouraging the patient voice and readership

This editorial for the British Journal of Dermatology provides an update from a patient editor point of view.

COMMENTARIES

Psoriasis treatment: no more room on the summit?

Lluís Puig, 
  • Page: 837
  • First Published: 05 September 2022

Linked Article: Blauvelt et al. Br J Dermatol 2022; 187:866–877.

How will brepocitinib cream compare with established treatments for mild-to-moderate eczema?

Stephanie J. Lax,  Aaron M. Drucker, 
  • Page: 838
  • First Published: 05 October 2022

Linked Article: Landis et al. Br J Dermatol 2022; 187:878–887.

Differences in cutaneous manifestations of COVID-19 during the Delta and Omicron waves revealed using the ZOE app

Mercè Grau-Pérez,  Ignacio Garcia-Doval, 
  • Page: 839
  • First Published: 23 September 2022

Linked Article: Visconti et al. Br J Dermatol 2022; 187:900–908.

Open Access

Understanding the impact of life with vulval lichen sclerosus

Vanitha Sivalingam,  Kajal Tamber, 
  • Page: 840
  • First Published: 02 September 2022

Linked Article: Arnold et al. Br J Dermatol 2022; 187:909–918.

Immune checkpoint inhibitor-induced cutaneous toxicities: they are not just random

Hanjae Lee,  Ohsang Kwon, 
  • Pages: 840-841
  • First Published: 02 September 2022

Linked Article: Nikolaou et al. Br J Dermatol 2022; 187:962–969.

Follicular T helper cells and cutaneous T-cell lymphomas

Werner Kempf, 
  • Pages: 841-842
  • First Published: 31 August 2022

Linked Article: Wang et al. Br J Dermatol 2022; 187:970–980.

Open Access

Sensitization to epoxy resin systems in the wind turbine industry: an undesirable side-effect of renewable energies

Richard Brans, 
  • Pages: 842-843
  • First Published: 05 October 2022

Linked Article: Christiansen et al. Br J Dermatol 2022; 187:988–996.

Open Access

Atypical clinical manifestation and protracted latency are observed in the emerging variant of checkpoint inhibitor-associated bullous pemphigoid

Khalaf Kridin,  Christoph M. Hammers, 
  • Pages: 843-844
  • First Published: 30 September 2022

Linked Article: Kawsar et al. Br J Dermatol 2022; 187:981–987.

Open Access

Transcriptomic analysis identifies regulators of the Wnt signalling and hypoxia-inducible factor pathways as possible mediators of androgenetic alopecia

Michael Philpott, 
  • Page: 845
  • First Published: 05 October 2022

Linked Article: Liu et al. Br J Dermatol 2022; 187:936–947.

Evidence-Based Dermatology

SYSTEMATIC REVIEW

Open Access

Pain measurement in painful skin conditions and rheumatoid arthritis randomized controlled trials: a scoping review to inform pain measurement in hidradenitis suppurativa

Samar B. Hasan,  Riham Gendra,  JaBreia James,  Delyth Morris,  Lauren A.V. Orenstein,  John R. Ingram, 
  • Pages: 846-854
  • First Published: 12 August 2022
Pain measurement in painful skin conditions and rheumatoid arthritis randomized controlled trials: a scoping review to inform pain measurement in hidradenitis suppurativa*

The review looked at the tools used to measure pain in painful skin conditions and how Pain NRS and VAS were used in randomized clinical trials (RCTs) of painful skin conditions and rheumatoid arthritis. The results showed a discrepancy in how pain NRS/VAS were measured in the trials. In addition, the mean difference was the most common method of reporting pain.

Plain language summary available online

CRITICALLY APPRAISED TOPIC

Topical treatments in the management of keloids and hypertrophic scars: a critically appraised topic

Sina J. Ghadiri,  Ewa Kloczko,  Carsten Flohr, 
  • Pages: 855-856
  • First Published: 17 August 2022

Is routine laboratory testing in healthy young patients taking isotretinoin necessary: a critically appraised topic

Andrew Affleck,  David Jackson,  Hywel C. Williams,  Patricia Chavez,  Joerg Albrecht, 
  • Pages: 857-865
  • First Published: 20 August 2022

Original articles

CLINICAL TRIALS

Open Access

Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1)

Andrew Blauvelt,  Alexa B. Kimball,  Matthias Augustin,  Yukari Okubo,  Michael M. Witte,  Claudia Rodriguez Capriles,  Angelina Sontag,  Vipin Arora,  Olawale Osuntokun,  Bruce Strober, 
  • Pages: 866-877
  • First Published: 06 July 2022
Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1)*

The primary efficacy endpoints were met, with significantly greater improvements in clinical response observed with mirikizumab than with placebo at the end of the induction period. sPGA(0,1) response rates were superior in the mirikizumab arm (n(%) [95% confidence interval; CI], mirikizumab: 293(69.3) [64.9-73.7]; placebo: 7(6.5) [1.9, 11.2]; P < 0.001) compared with placebo at Week 16.

Linked Comment: L. Puig. Br J Dermatol 2022; 187:837.

Plain language summary available online

Open Access

Efficacy and safety of topical brepocitinib for the treatment of mild-to-moderate atopic dermatitis: a phase IIb, randomized, double-blind, vehicle-controlled, dose-ranging and parallel-group study

Megan N. Landis,  Mark Arya,  Stacy Smith,  Zoe Draelos,  Lisa Usdan,  Sanela Tarabar,  Vivek Pradhan,  Sudeepta Aggarwal,  Christopher Banfield,  Elena Peeva,  Michael S. Vincent,  Vanja Sikirica,  Jason Xenakis,  Jean S. Beebe, 
  • Pages: 878-887
  • First Published: 20 August 2022
Efficacy and safety of topical brepocitinib for the treatment of mild-to-moderate atopic dermatitis: a phase IIb, randomized, double-blind, vehicle-controlled, dose-ranging and parallel-group study*

Brepocitinib, a TYK2/JAK1 inhibitor, is being investigated as a topical cream treatment for atopic dermatitis (AD). In a phase IIb, randomised, double-blind study, brepocitinib was effective and well tolerated in participants with mild-to-moderate AD, although further study with a larger population and longer treatment duration is required.

Linked Comment: S.J. Lax and A.M. Drucker. Br J Dermatol 2022; 187:838.

Plain language summary available online

Open Access

Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials

Eric L. Simpson,  Joseph F. Merola,  Jonathan I. Silverberg,  Kristian Reich,  Richard B. Warren,  Delphine Staumont-Sallé,  Giampiero Girolomoni,  Kim Papp,  Marjolein de Bruin-Weller,  Jacob P. Thyssen,  Rebecca Zachariae,  Christiana K. Olsen,  Andreas Wollenberg, 
  • Pages: 888-899
  • First Published: 09 September 2022
Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials*

Tralokinumab, an anti-interleukin-13 biologic for the treatment of atopic dermatitis (AD), has provided significant and early improvements in signs and extent of AD in key Phase 3 clinical trials and was well tolerated, with a safety profile comparable to placebo. This study comprehensively assessed the safety profile of tralokinumab using data from five placebo-controlled trials in adult patients with moderate-to-severe AD, finding that overall incidence and rate of adverse events (AEs) was similar between tralokinumab and placebo in the initial treatment period (16 weeks) and did not increase over 52 weeks of continued treatment. Common AEs occurring more frequently with tralokinumab included conjunctivitis and injection site reaction.

Plain language summary available online

EPIDEMIOLOGY

Open Access

Cutaneous manifestations of SARS-CoV-2 infection during the Delta and Omicron waves in 348 691 UK users of the UK ZOE COVID Study app

Alessia Visconti,  Benjamin Murray,  Niccolò Rossi,  Jonathan Wolf,  Sebastien Ourselin,  Tim D. Spector,  Esther E. Freeman,  Veronique Bataille,  Mario Falchi, 
  • Pages: 900-908
  • First Published: 22 July 2022
Cutaneous manifestations of SARS-CoV-2 infection during the Delta and Omicron waves in 348 691 UK users of the UK ZOE COVID Study app*

Odds ratios in adults testing positive for COVID-19 of self-reporting some of the typical COVID-19 symptoms and skin signs of COVID-19 infection. Results are based on 198 609 users of the ZOE COVID Study App that self-reported their symptoms during the Delta wave and 198 609 users matched for age, sex, vaccination status and self-reported eczema diagnosis that self-reported their symptoms during the Omicron wave. The OR for anosmia (13·4, 95% confidence interval 13·1–13·8) is not shown for the Delta wave to improve visualization.

Linked Comment: M. Grau-Pérez and I. Garcia-Doval. Br J Dermatol 2022; 187:839.

Plain language summary available online

OUTCOMES AND QUALITATIVE RESEARCH

Open Access

Living with vulval lichen sclerosus: a qualitative interview study

Susanne Arnold,  Sheryl Fernando,  Sophie Rees, 
  • Pages: 909-918
  • First Published: 13 July 2022
Living with vulval lichen sclerosus: a qualitative interview study*

Vulval lichen sclerosus can have a profound impact on quality of life and self-identity but is relatively under-explored from the perspective of those living with the condition. Using qualitative methods, the aim of this study was to explore individuals’ experiences of vulval lichen sclerosus and its impact on their lives. We developed three themes to interpret the experience of living with vulval lichen sclerosus: missed opportunities, learning to live with a long-term condition, and a secret life.

Linked Comment: V. Sivalingam and K. Tamber. Br J Dermatol 2022; 187:840.

Plain language summary available online

Open Access

Content validity of the Recap of atopic eczema (RECAP) instrument in Dutch, English and German to measure eczema control in young people with atopic eczema: a cognitive interview study

Michaela Gabes,  Aviël Ragamin,  Arabella Baker,  Gesina Kann,  Theresa Donhauser,  Daniela Gabes,  Laura Howells,  Kim S. Thomas,  Jart A.F. Oosterhaven,  Suzanne G.M.A. Pasmans,  Marie L. Schuttelaar,  Christian Apfelbacher, 
  • Pages: 919-926
  • First Published: 16 July 2022

Factors associated with treatment satisfaction in patients with hidradenitis suppurativa: results from the Global VOICE project

Bria Midgette,  Andrew Strunk,  Oleg Akilov,  Afsaneh Alavi,  Christine Ardon,  Falk G. Bechara,  Arnon D. Cohen,  Steven Cohen,  Steven Daveluy,  Véronique del Marmol,  Maïa Delage,  Solveig Esmann,  Shani Fisher,  Evangelos J. Giamarellos-Bourboulis,  Amelia Glowaczewska,  Noah Goldfarb,  Elena Gonzalez Brant,  Øystein Grimstad,  Sandra Guilbault,  Iltefat Hamzavi,  Rosalind Hughes,  John R. Ingram,  Gregor B.E. Jemec,  Qiang Ju,  Naomi Kappe,  Brian Kirby,  Joslyn S. Kirby,  Michelle A. Lowes,  Lukasz Matusiak,  Stella Micha,  Robert Micheletti,  Angela P. Miller,  Dagfinn Moseng,  Haley Naik,  Aude Nassif,  Georgios Nikolakis,  So Yeon Paek,  Jose Carlos Pascual,  Errol Prens,  Barry Resnik,  Hassan Riad,  Christopher Sayed,  Saxon D. Smith,  Yssra Soliman,  Jacek C. Szepietowski,  Jerry Tan,  Linnea Thorlacius,  Thrasyvoulos Tzellos,  Hessel H. van der Zee,  Bente Villumsen,  Lanqi Wang,  Christos Zouboulis,  Amit Garg, 
  • Pages: 927-935
  • First Published: 30 July 2022

Plain language summary available online

TRANSLATIONAL RESEARCH

Open Access

Insights into male androgenetic alopecia using comparative transcriptome profiling: hypoxia-inducible factor-1 and Wnt/β-catenin signalling pathways

Qingmei Liu,  Yulong Tang,  Yan Huang,  Ji’an Wang,  Kai Yang,  Yuting Zhang,  Weilin Pu,  Jing Liu,  Xiangguang Shi,  Yanyun Ma,  Chunya Ni,  Yue Zhang,  Yifei Zhu,  Haiyang Li,  Jiucun Wang,  Jinran Lin,  Wenyu Wu, 
  • Pages: 936-947
  • First Published: 21 July 2022
Insights into male androgenetic alopecia using comparative transcriptome profiling: hypoxia-inducible factor-1 and Wnt/β-catenin signalling pathways*

We identified a number of differentially expressed genes and pathways between balding vertex and non-balding occipital AGA HFs by using whole transcriptome analyses. We identified pathways not previously reported in AGA, such as the HIF-1 signaling pathway. Moreover, we verified that HIF-1 pathway-related genes (EGLN1, EGLN3) and Wnt pathway inhibitors (PEDF, SFRP2) played important roles in DPC activity, hair growth, and hair cycle, suggesting that these genes may be potentially utilized as therapeutic targets for AGA.

Linked Comment: M. Philpott. Br J Dermatol 2022; 187:845.

Plain language summary available online

Germline intergenic duplications at Xq26.1 underlie Bazex–Dupré–Christol basal cell carcinoma susceptibility syndrome

Yanshan Liu,  Siddharth Banka,  Yingzhi Huang,  Jonathan Hardman-Smart,  Derek Pye,  Antonio Torrelo,  Glenda M. Beaman,  Marcelo G. Kazanietz,  Martin J. Baker,  Carlo Ferrazzano,  Chenfu Shi,  Gisela Orozco,  Stephen Eyre,  Michel van Geel,  Anette Bygum,  Judith Fischer,  Zosia Miedzybrodzka,  Faris Abuzahra,  Albert Rübben,  Sara Cuvertino,  Jamie M. Ellingford,  Miriam J. Smith,  D. Gareth Evans,  Lizelotte J.M.T. Weppner-Parren,  Maurice A.M. van Steensel,  Iskander H. Chaudhary,  D. Chas Mangham,  John T. Lear,  Ralf Paus,  Jorge Frank,  William G. Newman,  Xue Zhang, 
  • Pages: 948-961
  • First Published: 20 August 2022
Germline intergenic duplications at Xq26.1 underlie Bazex–Dupré–Christol basal cell carcinoma susceptibility syndrome*

In this paper we show that Bazex-Dupré-Christol syndrome (BDCS), an X-linked disorder of susceptibility to basal cell carcinomas, is caused by non-coding Xq26.1 duplications that likely result in dysregulation of ARHGAP36, encoded by a flanking gene.

Plain language summary available online

MEDICAL DERMATOLOGY

Clinical associations and classification of immune checkpoint inhibitor-induced cutaneous toxicities: a multicentre study from the European Academy of Dermatology and Venereology Task Force of Dermatology for Cancer Patients

Vasiliki A. Nikolaou,  Zoe Apalla,  Cristina Carrera,  Davide Fattore,  Pietro Sollena,  Julia Riganti,  Sonia Segura,  Azael Freites-Martinez,  Konstantinos Lallas,  Maria Concetta Romano,  Chrysa Oikonomou,  Michela Starace,  Meletios A. Dimopoulos,  Athanassios Kyrgidis,  Elizabeth Lazaridou,  Priscila Giavedoni,  Maria Carmela Annunziata,  Ketty Peris,  Maria Echeverría,  Emilio Lopez-Tujillo,  Konstandinos Syrigos,  Chryssoula Papageorgiou,  Sebastian Podlipnik,  Gabriella Fabbrocini,  Ana C. Torre,  Christina Kemanetzi,  Lorena Villa-Crespo,  Aimilios Lallas,  Alexander J. Stratigos,  Vincent Sibaud, 
  • Pages: 962-969
  • First Published: 21 July 2022
Clinical associations and classification of immune checkpoint inhibitor-induced cutaneous toxicities: a multicentre study from the European Academy of Dermatology and Venereology Task Force of Dermatology for Cancer Patients*

Linked Comment: H. Lee and O. Kwon. Br J Dermatol 2022; 187:840-841.

Plain language summary available online

Open Access

Primary cutaneous peripheral T-cell lymphomas with a T-follicular helper phenotype: an integrative clinical, pathological and molecular case series study

Luojun Wang,  Delphine Rocas,  Stéphane Dalle,  Nouhoum Sako,  Laura Pelletier,  Nadine Martin,  Aurélie Dupuy,  Nadia Tazi,  Brigitte Balme,  Béatrice Vergier,  Marie Beylot-Barry,  Agnès Carlotti,  Martine Bagot,  Maxime Battistella,  Guillaume Chaby,  Saskia Ingen-Housz-Oro,  Philippe Gaulard,  Nicolas Ortonne, 
  • Pages: 970-980
  • First Published: 27 July 2022
Primary cutaneous peripheral T-cell lymphomas with a T-follicular helper phenotype: an integrative clinical, pathological and molecular case series study*

There is a group of cutaneous lymphomas that express TFH markers that do not appear to correspond to existing WHO diagnostic entities. This is the first large original series of patients with a diagnosis of primary cutaneous peripheral T-cell lymphomas with a T-follicular helper phenotype (pcTFH-PTCL) to be molecularly characterised. pcTFH-PTCL may be a standalone group of cutaneous lymphomas with clinicopathological and molecular characteristics that overlap with those of systemic TFH lymphomas, and does not belong to known diagnostic groups of cutaneous lymphoma.

Linked Comment: W. Kempf. Br J Dermatol 2022; 187:841–842.

Plain language summary available online

Checkpoint inhibitor-associated bullous cutaneous immune-related adverse events: a multicentre observational study

Anusuya Kawsar,  Charlotte Edwards,  Pooja Patel,  Richard M. Heywood,  Aakriti Gupta,  Jasmine Mann,  Christopher Harland,  Kara Heelan,  James Larkin,  Paul Lorigan,  Catherine A. Harwood,  Rubeta N. Matin,  Louise Fearfield, 
  • Pages: 981-987
  • First Published: 17 August 2022
Checkpoint inhibitor-associated bullous cutaneous immune-related adverse events: a multicentre observational study*

This is the largest multicentre, observational study conducted in the UK, demonstrating an overall incidence of bullous cutaneous irAEs associated with CPI of 0·3%. Clinical presentation may vary, with pruritus and non-bullous variants appearing similar to other cutaneous toxicities. Time to onset appears later than with other cutaneous toxicities (12 months) and can occur after discontinuation of therapy. Interruption of CPI is often needed. Our study demonstrates this occurs mostly in men, older age groups and is associated with BRAF wildtype in MM patients. It is important for clinicians to recognize this condition promptly, so early optimal management is initiated to reduce interruptions to CPI and improve overall patient outcomes and tumour response.

Linked Comment: K. Kridin and C.M. Hammers. Br J Dermatol 2022; 187:843–844.

Plain language summary available online

Open Access

Prevalence of skin sensitization and dermatitis among epoxy-exposed workers in the wind turbine industry

Alexandra G. Christiansen,  Ole Carstensen,  Mette Sommerlund,  Per A. Clausen,  Jakob H. Bønløkke,  Vivi Schlünssen,  Marléne Isaksson,  Sigrun A. J. Schmidt,  Henrik A. Kolstad, 
  • Pages: 988-996
  • First Published: 16 August 2022

Linked Comment: R. Brans. Br J Dermatol 2022; 187:842–843.

Plain language summary available online

Correspondence

PERSPECTIVES

Multicentre Selective Lymphadenectomy Trial 1: key primary data remain unavailable

Anthony Dixon,  Athanassios Kyrgidis,  Christopher Zachary,  John Dixon,  Catalin Popescu,  Michael Sladden,  Zoe Apalla,  Stuart Anderson,  Giuseppe Argenziano,  Demitrios Ioannides,  Alexander Nirenberg,  Aimillios Lallas,  Samuel Zagarella,  Caterina Longo,  Harvey Smith,  Howard Steinman,  Thrasivoulos Tzellos,  Lloyd Cleaver,  Ken Leahey,  Christos C. Zouboulis,  J. Meirion Thomas, 
  • Pages: 997-998
  • First Published: 22 June 2022
Open Access

Safeguarding online research integrity: concerns from recent experience

Rachael M. Hewitt,  Catherine Purcell,  Chris Bundy, 
  • Pages: 999-1000
  • First Published: 13 July 2022

Where’s the colour? Advocating for morphological and antioppressive fluencies in dermatology

Gagandeep Singh,  Onye Nnorom,  Erin Dahlke, 
  • Pages: 1001-1002
  • First Published: 03 August 2022

Dermatological considerations and culturally sensitive recommendations for women who wear the hijab

Rafey Rehman,  Mahfujul Haque,  Marissa Ceresnie,  Iltefat H. Hamzavi,  Fatima Fahs,  Tasneem F. Mohammad, 
  • Pages: 1003-1004
  • First Published: 03 August 2022
Dermatological considerations and culturally sensitive recommendations for women who wear the hijab

Currently, there is little guidance in the literature on how to advise patients who wear the hijab on hijab-related dermatoses. This manuscript describes hijab-related dermatoses and provides culturally sensitive recommendations that can be used in conjunction with standard treatments to provide more holistic care for these patients.

Open Access

The sound of silence: where are the voices of patients in eczema guideline development?

Korey Capozza,  Anne Vastrup,  Andrew Proctor,  Amanda Roberts,  Mario Picozza,  Rachael Manion,  Cheryl Talent,  Marjolaine Hering,  Stephanie Merhand,  Melanie Funk,  Kathryn Z. Tullos,  Bernd W.M. Arents, 
  • Pages: 1005-1006
  • First Published: 16 August 2022

Using the upgrade criteria of the European Psoriasis Consensus is best practice care according to the people-centred healthcare concept of the World Health Organization

Ulrich Mrowietz,  Matthias Augustin, 
  • Pages: 1007-1008
  • First Published: 16 August 2022

Is it necessary to wear sunscreen indoors?

Brian L. Diffey, 
  • Pages: 1009-1010
  • First Published: 23 August 2022

RESEARCH LETTERS

Open Access

Cutaneous manifestations of lymphoid-variant hypereosinophilic syndrome

Claire Laurent,  Guillaume Lefèvre,  Jean-Emmanuel Kahn,  Delphine Staumont-Salle,  Renaud Felten,  Marie Puget,  Thomas Moulinet,  Irène Machelart,  David Launay,  Estelle Charvet,  Jean David Bouaziz,  Marie Jachiet,  Alexandra Espitia,  Alfred Mahr,  Christian Le Clech,  Marion Malphettes,  Cécile Morice,  Samia Mourah,  Hélène Moins-Teisserenc,  François Lifermann,  Karine Soulier-Guérin,  Alban Villate,  Chloé Baillou,  Aurélie Grados,  Ailsa Robbins,  Noemie Abisror,  Martine Bagot,  David Boutboul,  Kewin Panel,  Marie-Dominique Vignon-Pennamen,  Jacqueline Rivet,  Maxime Battistella,  Matthieu Groh,  Adèle de Masson, on behalf of the CEREO network , 
  • Pages: 1011-1013
  • First Published: 21 July 2022
Cutaneous manifestations of lymphoid-variant hypereosinophilic syndrome

Psychosocial burden of frontal fibrosing alopecia: a qualitative interview study

Madison K. Cook,  Patrick O. Perche,  Jonathan C. White,  Steven R. Feldman,  Lindsay C. Strowd, 
  • Pages: 1013-1015
  • First Published: 22 July 2022

Low predictive value of questionnaire-based diagnosis of hidradenitis suppurativa

Jonathan Koptyev,  Andrew Strunk,  Amit Garg, 
  • Pages: 1015-1017
  • First Published: 23 July 2022

Nailfold videocapillaroscopy and serum vascular endothelial growth factor in probable COVID-19-induced chilblains: a cross-sectional study to assess microvascular impairment

Yora Mostmans,  Vanessa Smith,  Maurizio Cutolo,  Karin Melsens,  Salomé Battist,  Asma Benslimane,  Francis Corazza,  Bertrand Richert,  Olivier Michel,  Athanassios Kolivras, 
  • Pages: 1017-1019
  • First Published: 02 August 2022
Open Access

Time to next treatment and safety assessment in cutaneous-T-cell lymphomas: a retrospective analysis on patients treated with bexarotene and acitretin

Gabriele Roccuzzo,  Paolo Fava,  Gianluca Avallone,  Carola Aquino,  Sara Boskovic,  Nicole Macagno,  Simone Ribero,  Pietro Quaglino, 
  • Pages: 1019-1021
  • First Published: 13 July 2022
Open Access

Real-world data on the effectiveness, safety and drug survival of dupilumab: an analysis from the TREATgermany registry

Dora Stölzl,  Nicole Sander,  Annice Heratizadeh,  Eva Haufe,  Inken Harder,  Susanne Abraham,  Luise Heinrich,  Andreas Kleinheinz,  Andreas Wollenberg,  Elke Weisshaar,  Knut Schäkel,  Konstantin Ertner,  Franca Wiemers,  Julia Wildberger,  Margitta Worm,  Ralph von Kiedrowski,  Isaak Effendy,  Andrea Asmussen,  Matthias Augustin,  Mario Pawlak,  Michael Sticherling,  Alexander Zink,  Melanie Hilgers,  Christiane Handrick,  Sven Quist,  Beate Schwarz,  Petra Staubach-Renz,  Magnus Bell,  Sun-Hei Hong-Weldemann,  Bernhard Homey,  Jens-Joachim Brücher,  Jochen Schmitt,  Thomas Werfel,  Stephan Weidinger,  the TREATgermany study group , 
  • Pages: 1022-1024
  • First Published: 27 July 2022
Real-world data on the effectiveness, safety and drug survival of dupilumab: an analysis from the TREATgermany registry

This interim analysis from the atopic dermatitis registry TREATgermany shows robust long-term efficacy, favourable safety and high persistence of dupilumab under real life conditions.

Patient and disease characteristics associated with psychiatric symptoms and impaired quality of life in pityriasis rubra pilaris

Antonio Ji-Xu,  Donald K. Lei,  Scott Worswick,  Nolan J. Maloney,  Mindy M. Kim,  Lauren Cutler, 
  • Pages: 1024-1026
  • First Published: 27 July 2022

Folliculitis decalvans and dystrophic epidermolysis bullosa: a significant association

Bruno Matard,  Emmanuelle Bourrat,  Marine Cavalié,  Christine Chiaverini,  Pascal Reygagne, 
  • Pages: 1026-1028
  • First Published: 29 July 2022
Folliculitis decalvans and dystrophic epidermolysis bullosa: a significant association

This work reports 30 cases of folliculitis decalvans (FD) in patients with dystrophic epidermolysis bullosa (DEB) among a cohort of 125 DEB patients seen between 2010 and 2021 in 2 French expert centers for the management of inherited epidermolysis bullosa. Such an association between two rare diseases cannot be fortuitous and implies a physiopathological link that we discuss in this paper. This association is a new significant fact to add to the reflexion on FD causes, suggesting that skin abnormality of DEB could act as a factor of a specific skin barrier alteration which could favor FD. Scarring alopecia with tufted folliculitis and pustules on inflamed skin at the vertex of a woman with dominant dystrophic epidermolysis bullosa.

Open Access

Regaining adequate treatment responses in patients with psoriasis who discontinued dose reduction of adalimumab, etanercept or ustekinumab

Lara S. van der Schoot,  Selma Atalay,  Marisol E. Otero,  Wietske Kievit,  Juul M.P.A. van den Reek,  Elke M.G.J. de Jong, 
  • Pages: 1028-1030
  • First Published: 27 July 2022

Lichen sclerosus in female patients is associated with an increased risk of metabolic syndrome and cardiovascular comorbidities: a retrospective cohort review

Alison Ranum,  Rebecca Freese,  Vidhyalakshmi Ramesh,  David R. Pearson, 
  • Pages: 1030-1032
  • First Published: 10 August 2022

COVID-19 pandemic-associated chilblains: more links for SARS-CoV-2 and less evidence for high interferon type I systemic response

Didier Bessis,  Sophie Trouillet-Assant,  Léo-Paul Secco,  Nathalie Bardin,  Brigitte Blanc,  Véronique Blatière,  Christine Chable-Bessia,  Christophe Delfour,  Céline Girard,  Jean-Christophe Richard,  Nathalie Gros,  Vincent Le Moing,  Nicolas Molinari,  Valérie Pallure,  Amandine Pisoni,  Nadia Raison-Peyron,  Elisa Reynaud,  Émilie Schwob,  Rémi Pescarmona,  Quentin Samaran,  Marjolaine Willems,  Thierry Vincent,  Mircea T. Sofonea,  Alexandre Belot,  Édouard Tuaillon, 
  • Pages: 1032-1035
  • First Published: 16 August 2022
Open Access

A qualitative study of patients’ experiences of screening for psoriatic arthritis

Christine A. Silverthorne,  Clive Bowen,  Jane Lord,  Neil McHugh,  William Tillett,  Emma Dures,  Anya Lissina, 
  • Pages: 1035-1037
  • First Published: 17 August 2022

Progression of in situ and early invasive cutaneous squamous cell carcinomas concurrent with successful target tumour response to a programmed death-1 inhibitor

Kelly McCoy,  Jennifer DeSimone, 
  • Pages: 1037-1038
  • First Published: 17 August 2022
Progression of in situ and early invasive cutaneous squamous cell carcinomas concurrent with successful target tumour response to a programmed death-1 inhibitor

Qualitative analysis of the impact of atopic dermatitis on caregivers

Richard W. Kim,  Kelly Barta,  Wendy S. Begolka,  Korey Capozza,  Sanaz Eftekhari,  Kathryn Tullos,  Natalie Tomaszewski,  Claire Snell-Rood,  Katrina Abuabara, 
  • Pages: 1038-1041
  • First Published: 16 August 2022

The quantitative impact of atopic dermatitis on caregivers across multiple life domains

Richard W. Kim,  Kelly Barta,  Wendy S. Begolka,  Korey Capozza,  Sanaz Eftekhari,  Kathryn Tullos,  Natalie Tomaszewski,  Claire Snell-Rood,  Katrina Abuabara, 
  • Pages: 1041-1043
  • First Published: 03 September 2022

Three new founder mutations in Chinese patients with Nagashima-type palmoplantar keratoderma

Juan Liu,  Zhiming Chen,  Linghan Hu,  Zhongya Song,  Ran Mo,  Lemuel Shui-Lun Tsang,  Yihe Liu,  Xin Huang,  Zhuoqing Gong,  Ruiyu Xiang,  Zhimiao Lin,  Yong Yang, 
  • Pages: 1043-1045
  • First Published: 17 August 2022
Open Access

A translation re-initiation variant in KLHL24 also causes epidermolysis bullosa simplex and dilated cardiomyopathy via intermediate filament degradation

Mathilde C.S.C. Vermeer,  Mohammad Al-Shinnag,  Herman H.W. Silljé,  Antonio Esquivel Gaytan,  Dedee F. Murrell,  Julie McGaughran,  Wei Melbourne,  Timothy Cowan,  Peter C. van den Akker,  Karin Y. van Spaendonck-Zwarts,  Peter van der Meer,  Maria C. Bolling, 
  • Pages: 1045-1048
  • First Published: 17 August 2022
A translation re-initiation variant in KLHL24 also causes epidermolysis bullosa simplex and dilated cardiomyopathy via intermediate filament degradation

This study shows that gain-of-function variants in KLHL24 causing EBS and DCM, do not only originate in the start-codon and suggest that any nonsense-inducing variant affecting nucleotides c.4_84 will likely cause the same effect on protein level and a similar potential lethal phenotype.

Plasma cells and acute rejection of a near-total face transplant: an incidental finding or an evolving plasma-cell-mediated rejection?

Rebecca Knackstedt,  Wilma Bergfeld,  Luis Antonio Sardiña,  Bijan Eghtesad,  Maria Siemionow,  Risal Djohan, 
  • Pages: 1048-1050
  • First Published: 17 August 2022

Monkeypox: a new differential diagnosis when addressing genital ulcer disease

Joseph Griffiths-Acha,  Miguel Vela-Ganuza,  Claudia Sarró-Fuente,  José Luis López-Estebaranz, 
  • Pages: 1050-1052
  • First Published: 17 August 2022
Monkeypox: a new differential diagnosis when addressing genital ulcer disease

We describe a case of genital ulcer and inguinal adenopathies that were attributable to monkeypox virus infection. We suggest clinicians adopt a low threshold for suspicion, particularly when evaluating genital ulcer disease.

Open Access

Giant congenital melanocytic naevus with a novel CUX1–BRAF fusion mutation treated with trametinib

Vered Molho-Pessach,  Stav Hartshtark,  Sharon Merims,  Michal Lotem,  Nadia Caplan,  Hila Alfassi,  Alex Maly,  Gal Goldstein,  Rakefet Sidlik Muskatel, 
  • Pages: 1052-1054
  • First Published: 28 August 2022
Open Access

Consensus on the clinical management of chronic radiation dermatitis and radiation fibrosis: a Delphi survey

Britney N. Wilson,  Rohan Shah,  Christian Menzer,  Abdullah Aleisa,  Mary D. Sun,  Bernice Y. Kwong,  Ben H. Kaffenberger,  Lucia Seminario-Vidal,  Christopher A. Barker,  Michael D. Stubblefield,  Paul B. Romesser,  Gabriella Fabbrocini,  Murad Alam,  Farah Abdulla,  Brittany Dulmage,  Vincent Sibaud,  Milan Anadkat,  Jean-Michel Mazer,  Dhwani Parikh,  Beth McLellan,  Hugues Cartier,  Silvina Pugliese,  Albert Wolkerstorfer,  Hans-Joachim Laubach,  Nicole LeBoeuf,  Jonathan Leventhal,  Derrick C. Wan,  Jennifer Choi,  Thanh Nga Tran,  R. Rox Anderson,  Alina Markova,  Anthony Rossi, 
  • Pages: 1054-1056
  • First Published: 01 September 2022

LETTERS TO THE EDITOR

On the potential beneficial effects of indoor tanning

Pelle G. Lindqvist,  Elisabeth Epstein,  Mona Landin-Olsson, 
  • Page: 1057
  • First Published: 16 August 2022

Linked Article: Eden et al. Br J Dermatol 2022; 187:105–14.

On the potential beneficial effects of indoor tanning: reply from the authors

Martin Eden,  Rob Hainsworth,  Louisa G. Gordon,  Tracy Epton,  Paul Lorigan,  Lesley E. Rhodes,  Richard Marais,  Adele C. Green,  Katherine Payne, 
  • Pages: 1057-1058
  • First Published: 16 September 2022

Response to ‘Multicentre Selective Lymphadenectomy Trial 1: key primary data remain unavailable’

Mark B. Faries,  Alistair J. Cochran,  John F. Thompson, 
  • Pages: 1058-1059
  • First Published: 20 August 2022

Linked article: Dixon et al. Br J Dermatol 2022; https://doi.org/10.1111/bjd.21712

CORRIGENDA

Free Access

Corrigenda

  • Pages: 1060-1070
  • First Published: 04 December 2022

Free Access

Corrigenda

  • Pages: 1071-1082
  • First Published: 04 December 2022
Free Access

Corrigenda

  • Page: 1082
  • First Published: 04 December 2022

Free Access

Corrigenda

  • Pages: 1082-1083
  • First Published: 04 December 2022

ERRATUM

Free Access

Erratum

  • Page: 1083
  • First Published: 04 December 2022

Free Access

Erratum

  • Page: 1084
  • First Published: 04 December 2022

CORRESPONDENCE: IMAGE GALLERY

Atezolizumab-induced linear IgA bullous dermatosis

Silvia Aguilar-Duran,  John Mee,  Sanjay Popat,  Kara Heelan, 
  • Page: e193
  • First Published: 07 June 2022
Atezolizumab-induced linear IgA bullous dermatosis

A monkeypox virus infection mimicking primary syphilis

Martina Turco,  Fabrizio R. Mancuso,  Luigi Pisano, 
  • Pages: e194-e195
  • First Published: 25 August 2022
A monkeypox virus infection mimicking primary syphilis

Given the current monkeypox virus (MPXV) outbreak in at-risk men who have sex with men (MSM), clinicians should consider MPXV a differential diagnosis of syphilis, in any patient with a solitary painless genital nodule.

PLAIN LANGUAGE SUMMARIES

Free Access

A review of how pain is measured in painful skin conditions and rheumatoid arthritis studies, to determine pain measurement in future hidradenitis suppurativa trials

  • Page: e196
  • First Published: 04 December 2022

Linked Article: Hasan et al. Br J Dermatol 2022; 187:846–854.

Free Access

Skin reactions to immune checkpoint inhibitors used in cancer treatment

  • Page: e197
  • First Published: 04 December 2022

Linked Article: Nikolaou et al. Br J Dermatol 2022; 187:962–969.

Free Access

Insights into the biological differences in hair follicles of men with androgenetic alopecia

  • Page: e198
  • First Published: 04 December 2022

Linked Article: Liu et al. Br J Dermatol 2022; 187:936–947.

Free Access

The effectiveness and safety of topical brepocitinib for the treatment of mild-to-moderate atopic dermatitis

  • Page: e199
  • First Published: 04 December 2022

Linked Article: Landis et al. Br J Dermatol 2022; 187:878–887.

Free Access

Blistering skin side-effects associated with checkpoint inhibitor treatment for cancer

  • Page: e200
  • First Published: 04 December 2022

Linked Article: Kawsar et al. Br J Dermatol 2022; 187:981–987.

Free Access

Safety of tralokinumab for the treatment of atopic dermatitis

  • Page: e201
  • First Published: 04 December 2022

Linked Article: Simpson et al. Br J Dermatol 2022; 187:888–899.

Free Access

Patient experiences of living with vulval lichen sclerosus

  • Page: e202
  • First Published: 04 December 2022

Linked Article: Arnold et al. Br J Dermatol 2022; 187:909–918.

Free Access

Skin-related symptoms found in people with COVID-19 during the Delta and Omicron waves

  • Page: e203
  • First Published: 04 December 2022

Linked Article: Visconti et al. Br J Dermatol 2022; 187:900–908.

Free Access

Patient satisfaction with treatment for hidradenitis suppurativa

  • Page: e204
  • First Published: 04 December 2022

Linked Article: Midgette et al. Br J Dermatol 2022; 187:927–935.

Free Access

The effectiveness and safety of mirikizumab for treatment of psoriasis

  • Page: e205
  • First Published: 04 December 2022

Linked Article: Blauvelt et al. Br J Dermatol 2022; 187:866–877.

Free Access

The genetic cause of a rare skin cancer syndrome, Bazex–Dupré–Christol syndrome

  • Page: e206
  • First Published: 04 December 2022

Linked Article: Liu et al. Br J Dermatol 2022; 187:948–961.

Free Access

Skin sensitization and dermatitis among epoxy-exposed workers in the wind turbine industry

  • Page: e207
  • First Published: 04 December 2022

Linked Article: Christiansen et al. Br J Dermatol 2022; 187:988–996.

Free Access

Skin lymphomas of the T-follicular helper type

  • Page: e208
  • First Published: 04 December 2022

Linked Article: Wang et al. Br J Dermatol 2022; 187:970–980.

Free Access

关于如何在疼痛性皮肤病和类风湿关节炎研究中测量疼痛，以确定未来化脓性汗腺炎试验中的疼痛测量的综述

  • Page: e209
  • First Published: 04 December 2022

Linked Article: Hasan et al. Br J Dermatol 2022; 187:846–854.

Free Access

对癌症治疗中使用的免疫检查点抑制剂的皮肤反应

  • Page: e210
  • First Published: 04 December 2022

Linked Article: Nikolaou et al. Br J Dermatol 2022; 187:962–969.

Free Access

对雄激素性脱发男性毛囊生物学差异的见解

  • Page: e211
  • First Published: 04 December 2022

Linked Article: Liu et al. Br J Dermatol 2022; 187:936–947.

Free Access

外用 Brepocitinib 治疗轻中度特应性皮炎的有效性和安全性

  • Page: e212
  • First Published: 04 December 2022

Linked Article: Landis et al. Br J Dermatol 2022; 187:878–887.

Free Access

与癌症检查点抑制剂治疗相关的皮肤水疱副作用

  • Page: e213
  • First Published: 04 December 2022

Linked Article: Kawsar et al. Br J Dermatol 2022; 187:981–987.

Free Access

曲罗芦单抗治疗特应性皮炎的安全性

  • Page: e214
  • First Published: 04 December 2022

Linked Article: Simpson et al. Br J Dermatol 2022; 187:888–899.

Free Access

外阴硬化性苔藓患者的疾病体验

  • Page: e215
  • First Published: 04 December 2022

Linked Article: Arnold et al. Br J Dermatol 2022; 187:909–918.

Free Access

在德尔塔和奥密克戎疫情波次期间在新冠肺炎患者中发现的皮肤相关症状

  • Page: e216
  • First Published: 04 December 2022

Linked Article: Visconti et al. Br J Dermatol 2022; 187:900–908.

Free Access

患者对化脓性汗腺炎治疗的满意度

  • Page: e217
  • First Published: 04 December 2022

Linked Article: Midgette et al. Br J Dermatol 2022; 187:927–935.

Free Access

Mirikizumab 治疗银屑病的有效性和安全性

  • Page: e218
  • First Published: 04 December 2022

Linked Article: Blauvelt et al. Br J Dermatol 2022; 187:866–877.

Free Access

罕见皮肤癌综合征: Bazex-Dupré-Christol 综合征的遗传原因

  • Page: e219
  • First Published: 04 December 2022

Linked Article: Liu et al. Br J Dermatol 2022; 187:948–961.

Free Access

风力涡轮机行业暴露于环氧树脂的工人的皮肤过敏和皮炎

  • Page: e220
  • First Published: 04 December 2022

Linked Article: Christiansen et al. Br J Dermatol 2022; 187:970–980.

Free Access

T 滤泡辅助型皮肤淋巴瘤

  • Page: e221
  • First Published: 04 December 2022

Linked Article: Wang et al. Br J Dermatol 2022; 187:988–996.